Lexaria Bioscience Corp. LEXX
Last Post: 08/29/2024 4:31:46 PM
Board Marks: 0
Posts Today: 0
Board Views Today: 47
Welcome to Lexaria Bioscience Corp.
Lexaria Bioscience Corp’s ( NASDAQ: LEXX CSE: LXX ) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier delivery methods and increasing the effectiveness of fat-soluble active molecules and drugs.
The Company’s technology can be applied to many different drugs and other active ingredients such as vitamins in oral formats including tablets, capsules, oral suspensions – and even foods, beverages and topical preparations.
DehydraTECH:
increases bio-absorption by up to 5x,
reduces time of onset from up to 1 – 2 hours to just minutes
masks unwanted tastes. and
can reduce unwanted side effects by enabling lower overall dosing.
DehydraTECH is one of the world’s newest technologies specifically designed to improve the efficacy of orally administered bioactive molecules, including anti-viral drugs, nicotine, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and other molecules.
Companies with operations in over 100 countries around the world are examining DehydraTECH for possible use in the smokeless tobacco-derived nicotine industry, in the health and wellness industry, and more. Lexaria is investigating whether its technology might be useful for more effectively delivering drugs in the fight against certain viruses including SARS-CoV-2 that causes COVID-19. . Lexaria operates a federally-licensed in-house research laboratory and is building a robust intellectual property portfolio with 18 patents granted internationally as of Fall, 2020, and roughly 60 patents pending worldwide.
https://www.lexariabioscience.com/
Lexaria Bioscience Corp’s ( NASDAQ: LEXX CSE: LXX ) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier delivery methods and increasing the effectiveness of fat-soluble active molecules and drugs.
The Company’s technology can be applied to many different drugs and other active ingredients such as vitamins in oral formats including tablets, capsules, oral suspensions – and even foods, beverages and topical preparations.
DehydraTECH:
increases bio-absorption by up to 5x,
reduces time of onset from up to 1 – 2 hours to just minutes
masks unwanted tastes. and
can reduce unwanted side effects by enabling lower overall dosing.
DehydraTECH is one of the world’s newest technologies specifically designed to improve the efficacy of orally administered bioactive molecules, including anti-viral drugs, nicotine, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and other molecules.
Companies with operations in over 100 countries around the world are examining DehydraTECH for possible use in the smokeless tobacco-derived nicotine industry, in the health and wellness industry, and more. Lexaria is investigating whether its technology might be useful for more effectively delivering drugs in the fight against certain viruses including SARS-CoV-2 that causes COVID-19. . Lexaria operates a federally-licensed in-house research laboratory and is building a robust intellectual property portfolio with 18 patents granted internationally as of Fall, 2020, and roughly 60 patents pending worldwide.
https://www.lexariabioscience.com/
Lexaria Bioscience Corp. (NASDAQ: LEXX) Stock Message Board
Post
Subject
Author
Posted On
